Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: a randomized prospective surgical trial. The Intergroup Sentinel-Mamma (INSEMA)-Trial

Toral Reimer1, Gunter von Mincwitz2, Sibyle Lobid1, Guido Hildebrandt2, Carsten Denkert2, Valentina Nekljudova2, Günther Kundt2, Daniel Becker2, Bernd Gerber1

1Breast Center University of Rostock, Rostock, Germany; 2German Breast Group, Neu-Isenburg, Germany; 3Radiotherapie University of Rostock, Rostock, Germany; 4Institute of Pathology Charité, Berlin, Germany; 5Institute of Biostatistics University of Rostock, Rostock, Germany;

Email: insema@klinikueder-rostock.de; insema@gbg.de

Background

• Previous studies (NSABP B-04 / IBCSG 10-93) showed high rates of locoregional control achieved with multimodality therapy, even without axillary lymph node dissection (ALND).1,2
• Despite increasing evidence disfavoring ALND, it remains part of guidelines for breast cancer (BC) treatment.
• Current approaches should include improved imaging, pathological evaluation, planning of surgical and radiation therapy, and more effective systemic treatment, emphasizing the need for ongoing re-evaluation of “standard” local therapy.

INSEMA (NCT02466737) aims to show that early-stage BC patients with reduced extent of axillary surgery do not have inferior prognosis regarding invasive disease-free survival (IDFS) outcome.

Materials and Methods

Study design:
Patients with planned breast-conserving surgery (BCS) will be randomized in 1:1 ratio to no axillary surgery or sentinel lymph node biopsy (SLNB). Patients with SLNB and pN0 (sn) status will then be randomized to SLNB alone or completion ALND (Figure 1).

Statistical considerations:
• 1st recruitment: 5-year IDFS is considered to be 88%. Clinical non-inferiority is defined as a 5-year IDFS of ≥85% and hazard ratio <1.271 of the non-SLNB compared with SLNB group. Adjusting for 1:4 randomization, 936 events and 5,940 per-protocol patients are needed. Assuming a 5% exclusion rate from per-protocol analysis, 6,250 patients need to be randomized.
• 2nd randomization: 5-year IDFS is considered to be 81%. Clinical non-inferiority is defined as a 5-year IDFS of ≥76.5% and hazard ratio <1.271 of the SLNB alone compared with the completion ALND group. Local recurrence rate, 2.0% patients need to be randomized.

Main inclusion criteria:
• Histologically confirmed (core biopsy) unilateral primary invasive BC.
• Age at diagnosis ≥35 years.
• Preoperative imaging techniques with estimated tumor size of ≤5 cm (IT1/IT2 irrespective of hormone sensitivity or HER2 status).
• Clinically and sonographically tumor-free axilla prior to core biopsy (cN0/I0).
• In cases of cN0 and IT1, a negative core biopsy or fine needle aspiration biopsy of the sonographically suspected lymph node group is required before randomization.
• No clinical evidence for distant metastasis (M0).
• Planned BCS (R0 resection) with postoperative external whole-breast irradiation (conventional or hypofractionation).

Objectives

Primary objective is to compare IDFS after BCS (non-inferiority question)
• no axillary surgery vs SLNB patients (1st randomization).
• pN0 (sn) with SLNB alone vs pN0 (sn) with completion ALND (2nd randomization).

Secondary objectives are to compare
• IDFS after BCS (no ALND) or SLNB vs no surgery, axillary surgery vs SLNB alone, no axillary surgery vs pN0 (sn) with completion ALND,
• overall survival between arms,
• locoregional DFS (no tumor in ipsilateral breast or supraclavicular, subclavicular, internal mammary or axillary nodes) between arms in both randomizations,
• ipsilateral axillary recurrence rate,
• distant disease-free survival (DDFS),
• safety and quality of life between arms.
• IDFS in stratified subgroups and according to study site
• registration of delivered dose distribution in ipsilateral axilla levels I-III during postoperative whole-breast irradiation

Results

Recruitment started in September 2015 and is planned for 48 months at 130 German and 15 Austrian sites. So far, 159 patients have been recruited by 40 centres (Figure 2).
After a 5-year follow-up, final analysis is planned for 2024

Conclusions

INSEMA investigates if less axillary surgery is better by means of achieving the same oncological outcomes with less surgical intervention, which will result in fewer surgical complications. INSEMA should be discussed in context with other ongoing trials like SOUND (SLNB vs no SLNB in T1-tumours and BCS) or SENOMAC and POSNOC (SLNB alone vs ALND in 1-2 SLN-macrostases).

References

This presentation is the intellectual property of the author/presenter. Contact them at publications@gbg.de for permission to reprint and/or distribute.